Prenetics Global Limited Announces Proposed Public OfferingCHARLOTTE, N.C., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (“Prenetics” or the “Company”), a leading health sciences company, today announced that it has commenced a public offering of shares of its Class A Ordinary Shares (or prefunded warrants in lieu thereof) and common warrants (the “Offering”). The Company will allocate proceeds from the offering toward the global expansion of IM8, driven by its explosive growth, and the strategic accumulation of Bitcoin (BTC) as part of its pioneering dual-pronged health and wealth strategy.
Prenetics Completes $72 Million ACT Exit, Bolsters Cash and Bitcoin Treasury to Accelerate IM8’s Path to $100 Million ARRCHARLOTTE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (
NASDAQ: PRE), a leading consumer health sciences company, today announced the official completion of its divestment of ACT Genomics Co., Ltd. (“ACT”) to Delta Electronics, Inc. (TWSE:2308). This transaction marks a final step in Prenetics’ strategic exit from the clinical diagnostics sector, enabling the company to dedicate its resources and attention to its rapidly expanding consumer health initiatives.
Prenetics Announces CEO Danny Yeung Keynote at Token 2049 Singapore- Keynote: “IM8: The World’s Fastest-Growing Supplement Brand Powering Our Bitcoin Treasury
Prenetics’ IM8 Congratulates Global Ambassador and Shareholder - World No. 1 Aryna Sabalenka on Defending Her US Open ChampionshipCHARLOTTE, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (
NASDAQ: PRE), a leading health sciences company, and its premium supplement brand IM8, co-founded by David Beckham, today extends heartfelt congratulations to global ambassador and shareholder, World No. 1 tennis player Aryna Sabalenka, on successfully defending her singles championship at the 2025 US Open.
World No. 1 Tennis Star Aryna Sabalenka Joins Prenetics’ IM8 Health as Global Ambassador and ShareholderCHARLOTTE, N.C., June 26, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (
NASDAQ: PRE), a leading consumer health sciences company, announced today at a special event at Wimbledon House that IM8, its premium supplements brand co-founded by David Beckham, has partnered with world No. 1 tennis star Aryna Sabalenka as its newest global ambassador and shareholder. The announcement comes just days before the start of Wimbledon on June 30th, where Sabalenka will be competing as one of the tournament favorites.
Prenetics Becomes First Healthcare Company to Execute Aggressive Bitcoin Treasury Strategy, Secures $20M in BTC, Appoints Former OKEx COO to Board- Prenetics adopts proven corporate Bitcoin strategy inspired by MicroStrategy's ~$40B Bitcoin holdings and Metaplanet's meteoric treasury transformation
Prenetics Divests ACT Genomics to Delta Electronics as Part of up to US$71.78 Million TransactionCHARLOTTE, N.C., June 18, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (
NASDAQ: PRE) (“Prenetics”), a leading consumer health sciences company, today announced it has entered into a definitive agreement to divest its ownership in ACT Genomics Holdings Company Limited (“ACT Genomics”) to Delta Electronics, Inc. (TWSE: 2308) (“Delta”). Delta is a global leader in power management and smart green solutions, as well as a provider of healthcare technologies. The transaction regarding Delta’s acquisition of up to 100% ACT Genomics’ shareholdings is valued at up to US$71.78 million. Prenetics, holding a majority stake in ACT Genomics, will receive a gross proceed of approximately US$46 million in cash post-closing of the transaction and subject to customary release conditions. With a cash balance of US$44 million1, this divestment bolsters Prenetics financial position, increasing its pro-forma cash reserves to approximately US$86 million2 and with $117 million pro-forma short term assets3, while maintaining a debt-free balance sheet.
Prenetics Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, & Crypto Strategy Announcement SoonCHARLOTTE, N.C., June 12, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (
NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced unaudited financial results for the first quarter ended March 31, 2025, along with recent business updates.
IM8 Vibrante Miami: Fueling Wellness and Innovation with a Star-Studded EventDavid Beckham was Joined by Dr. Amy Shah, Dr. Jeremy London, Dr. James DiNicolantonio and Kendal Toole to Reinforce IM8’s Vision for Elite Wellness Accessible to All
Prenetics Acquires ACT Genomics; First M&A Deal since IPO, Set to Expand Footprint in Cancer GenomicsHONG KONG, Dec 16, 2022 - (ACN Newswire) - Prenetics Global Limited (
NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, is acquiring a majority stake of ACT, an Asia based genomics company specializing in precision oncology with operations in Hong Kong, Taiwan, Japan, Singapore, Thailand and the UK, for an upfront consideration consisting of 19.9 million shares of Prenetics common stock and US $20 million cash (the "transaction"). That is the first M&A deal Prenetics is to make since its listing, which will expand its footprint in the cancer genomics space, bringing it closer to realizing the vision of building an end-to-end health ecosystem. With the acquisition well underway, effective from January 1, 2023, Professor Tony Mok, Chairman of ACT, will join Prenetics Scientific Advisory Board.
Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap IndexLONDON AND HONG KONG, Nov 30, 2022 - (ACN Newswire) - Prenetics Global Limited (
NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced that its board of directors has authorized a share repurchase program, and that it has been included as a constituent stock in the MSCI Global Micro Cap Index (Hong Kong), with such inclusion to become effective after the U.S. market close today.
